Connect with us:

Facebook Twitter RSS

News & Updates

13 Aug 2013

HPV vaccine could also prevent oropharyngeal cancer, says IARC

A new study by the International Agency for Research on Cancer (IARC), in partnership with Costa Rican investigators and the United States National Cancer Institute (NCI), shows for the first time that the vaccine against human papillomavirus (HPV) types 16 and 18, which is used to prevent cervical cancer, also provides strong protection against oral HPV infections, known to be associated with cancer of the oropharynx and tonsils.

The Costa Rican HPV Vaccine Trial

The study, conducted in Costa Rica and published today in the journal PLOS ONE was initially designed to evaluate the vaccine’s efficacy against cervical cancer. It later included evaluation of the vaccine’s efficacy at other anatomical sites, including the oral cavity, where researchers established that the vaccine reduces oral infections with HPV 16 and 18 by more than 90%.

In 2004 and 2005, a total of 7466 healthy women aged 18–25 years received the HPV16/18 vaccine or hepatitis A vaccine as control. A total of 5840 participants provided oral specimens, which were used to evaluate the efficacy of the vaccine against oral HPV infections. The vaccine trial showed that the HPV16/18 vaccine reduced by 93% the prevalence of oral HPV16/18 infections 4 years after vaccination.

Global burden

HPV is better known for causing cervical cancer, which is the third most common cancer in women worldwide, with an estimated 530 000 new cases and 275 000 deaths in 2008. HPV types 16 and 18 are also associated with cancers in a variety of other locations, including the vulva, vagina, penis, anus, and oropharynx. The estimated number of new cases of cancer of the oropharynx (including the tonsils and the base of the tongue) is approximately 85 000 per year in both sexes worldwide, and men are 4 times more likely than women to be affected. However, the incidence of oropharyngeal cancer has increased significantly in recent years in the USA and Europe, particularly among men and in young people.

Potential for prevention

“The vaccine seems to provide strong protection against oral HPV infections with the viral types that cause most cancers of the oropharynx,” said Dr Rolando Herrero from IARC, lead author of the study. “There are many aspects of the disease that we still don’t understand, and we need more direct evidence that the vaccine prevents oropharyngeal cancer, but these results indicate that we may now have an important tool for primary prevention of these increasingly common malignancies.”

Risk factors and recent incidence trends

Most oropharyngeal cancers have traditionally been linked with heavy tobacco and alcohol consumption, but 30% of oropharyngeal cancers worldwide are now thought to be related to HPV infection, which is linked to sexual practices, such as oral sex.

A recent study in the USA showed that over the past 20 years, the rate of HPV detection in oropharyngeal tumour specimens increased from 16% to 70%, leading that study’s authors to postulate that in the next few decades in the USA there may be more cases of HPV-related oropharyngeal cancer than HPV-related cervical cancer.

“The results of our study demonstrated protection against oral HPV infection in women. If similar results are observed in men, vaccination of boys may become an important public health measure in areas where oropharyngeal and other HPV-related cancers are relatively common in men,” added Dr Herrero.

Prevention

Last month, another IARC study in partnership with NCI6 showed that antibodies to HPV16 could help detect oropharyngeal cancer several years before the clinical onset of the disease. Dr Christopher Wild, Director of IARC, concluded that “both these results show an exciting area of research that will hopefully lend itself to public health action and help reduce the burden of HPV-induced cancers in the medium term.”

Source: IARC

More publications

14 Dec 2016: Preserving fertility in girls and young women with cancer “haphazard” say experts 23 Dec 2015: 'Hematological Malignancies: from Mechanisms to Therapy' symposium - March 9/12, 2016 - Milan 02 Dec 2015: European cancer centres finally united in long-term collaborative partnerships 19 Nov 2015: SiRIC-Curie Call for translational research group leaders, Paris, France 20 Oct 2015: IARC Fellowships for Cancer Research 03 Aug 2015: Optimizing sharing of hospital biobank samples: new EurocanPlatform paper published in Science Translational Medicine 17 Jul 2015: 3rd EurocanPlatform Summer School in Translational Cancer Research: Portugal, 12 – 16 October 2015 17 Jul 2015: NCT Heidelberg School of Oncology Fellowship Program in Translational Cancer Research - Call for applications 01 Jul 2015: EurocanPlatform project engages directly with patient groups at ECPC AGM 19 Jun 2015: EurocanPlatform Translational Research Course 12th - 16th October - Save the Date! 13 May 2015: Catch up on all the latest from the EurocanPlatform project in the May 2015 Newsletter 14 Apr 2015: New EurocanPlatform paper published in PLOS One 31 Mar 2015: Launch of personalised medicine survey: Literacy among healthcare professionals 30 Mar 2015: OECI Cancer Days 2015 in Porto, Portugal 10 Mar 2015: Workshop on circulating biomarkers in cancer 19 Feb 2015: Meeting report from the second EurocanPlatform summer school on translational cancer research published in ecancermedicalscience 27 Jan 2015: The January 2015 Newsletter is here! 21 Jan 2015: Most types of cancer not due to “bad luck”, says IARC 06 Jan 2015: Brand new videos available from the 2nd Translational Research Course 08 Dec 2014: New conference report for the EurocanPlatform Chemoprevention Meeting published in ecancermedicalscience 20 Nov 2014: The November 2014 Newsletter is here! 13 Nov 2014: IARC/WHO Fellowships 05 Nov 2014: Research course on circulating tumor cells (CTC) at the Karolinska Institute 28 Oct 2014: Eighth Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice 03 Oct 2014: Core values for a new cancer culture: six centres create Cancer Core Europe 01 Sep 2014: EurocanPlatform paper published in the Journal of Oncology Practice 18 Aug 2014: 4th Annual meeting of EurocanPlatform project, October 25-26th 2014 04 Aug 2014: EurocanPlatform Translational Cancer Research Summer Course, Portugal, October 20-24, 2014 31 Jul 2014: The Summer 2014 Newsletter is here! 18 Jun 2014: Role for an experienced scientist available at the Curie Institute 20 May 2014: New science policy paper published in Molecular Oncology 19 Feb 2014: Workshop on "Tissue-based Biomarkers for Advancement of Personalized Cancer Treatment" 21 Jan 2014: The second Advanced Lecture Course on Translational Cancer Research 21 Jan 2014: OECI and ECPC - How Uniform Is Cancer Care? February 18th 2014 31 Oct 2013: FDA pulls ponatinib approval due to blood clots and narrowing of blood vessels 22 Oct 2013: Publications from within EurocanPlatform - Year 2 09 Oct 2013: IARC: Postdoctoral fellowships for training in cancer research 12 Sep 2013: VHIO-Fritz Bender Foundation joint International Symposium 13 Aug 2013: New ECPC Board of Directors 11 Jun 2013: EAPM Members Update: Discussion on the Data Protection Legislation 21 May 2013: Growing call to abandon impact factors 29 Apr 2013: New partnership between IARC and CRI to spur cancer research in Thailand and across South-East Asia 11 Apr 2013: OECI 2013 Oncology Days - including EurocanPlatform Session 08 Mar 2013: Spreading the cancer prevention message in Sierra Leone 25 Feb 2013: EAPM: Access to health data is essential for the development of new treatments 20 Feb 2013: Access to health data is essential for the development of new treatments, says European Alliance of Personalised Medicine 23 Jan 2013: Course in cancer genomics at EBI 26 Oct 2012: Scientists discover potential new 'roots' of breast cancer 19 Sep 2012: Personalised medicine promises radical improvements to healthcare in Europe